Infant Brain Injury, Cell Therapy and Real World Data

In this episode we go into the innovative world of placental cell therapy with Mark O’Neil and Moayed Hamza. Together, they share their journey in developing a novel cell therapy aimed at treating neonatal hypoxic ischemic encephalopathy (HIE), a leading cause of infant brain injury. Furthermore consider how BevelCloud’s distributed AI infrastructure with access to real world real-time data (imaging and text) can help assess cell therapy safety and efficacy in diverse populations, monitor its performance and and inform clinical trial design and planning.